Just waiting on highest dose group results for IMO-8400. The market won't get too excited - even if results show moderate to strong activity on their chosen B-cell lymphoma gene. Until the lymphoma trials start issuing news, we might not see much enthusiasm. Their Waldenström’s macroglobulinemia trial continues and this half should see start of ph1/2 trial in diffuse large B-cell lymphoma patients. Once we start getting some positive news and movement from these trials, some life should come back to this zombie of a stock.
News 
Market Data 
Discover 
